and 55 and 45 Gy in 25 fractions in all patients with N+ and/or ≥T3, prescribed to Planning Target Volume 1 and Planning Target Volume 2 respectively. The most common chemotherapy regimen was 5-fluorouracil and mitomycin based. Results: The median age was 63 years (range 32-84). 5, 10, 11 and 14 patients were respectively in stage I, II, IIIA and IIIB. A complete response was achieved in 34/38 (89.4%) patients evaluable for outcomes, one partial response in 1 patient, inoperable persistence of disease was observed in 1 patient and progressive disease in 2 patients (local and metastatic respectively). Acute grade 3 skin and grade 3 gastrointestinal toxicity was reported in 5% and 7.3% of patients, respectively; treatment breaks due to toxicity were required in 7.3% of patients. With a median follow up of 20 months, the 2-year overall survival and disease free survival were 90.4% and 92.3%. Conclusions: In our experience, intensity modulated radiotherapy with simultaneous integrated boost is feasible and allows the obtainment of excellent results data in terms of overall survival, local control and toxicity without several breaks due to acute toxicity.
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The role of radiochemotherapy in the management of anal cancer: a single institution experience A. Arcelli 1 , A. Guido 1 , S. Cammelli 1 , A. Galuppi 1 , G.P. Bianchi 2 , M. Pieri 1 , L. Tontini 1 , A. Cortesi 1 , A.G. Morganti 1 , G. Purpose/Objective: The purpose of this study was to retrospectively assess the clinical outcome in anal cancer patients treated with curative intent chemo-radiotherapy in terms of local control (LC), distant metastases-free survival (DMFS) and overall survival (OS). Materials and Methods: From January 2002 to December 2012, 125 patients were treated for anal carcinoma in our Department of Radiotherapy in Policlinico S. Orsola-Malpighi, Bologna. The treatment consisted of 3DCRT on the pelvis (median dose: 45 Gy /1.8 Gy) with concurrent chemotherapy (5-fluorouracil and Mitomycin-C). After a clinical response evaluation patients received a boost 2-3 weeks after the end of the 3D-CRT by either pulsed dose rate brachytherapy (80% of the patients, mean dose: 18.5 Gy) or without any interruption by external beam radiotherapy (20%, mean dose 16.4 Gy) in patients with controindications to brachytherapy. Exclusion criteria for brachytherapy were: initial diffusion of cancer > 2/3 of circumpherence of anal canal, initial extended diffusion at the perianal skin, presence of a residual >5 cm in longitudinal or >1,5 cm in deepth after 3D-CRT (first course) and the clinical controindication for anesthesia. LC, DMFS and OS were analyzed using Kaplan-Meier method. A comparison of the survival curves was performed using long rank test (univariate analysis). Results: Males were 31 (25%), females 94 (75%). Median age was 61 years (range 37-94 years), elderly patients (over 65 years-old) were 53 (42%). Tumor stage was T1 in 18 patients (14%), T2 in 45 patients (36%), T3 in 41 patients (33%), T4 in 21 patients (17%). Nodal stage was N0 in 71 patients (57%), N1 in 29 (23%), N2 in 13 (10%). The histology was squamouscell carcinoma (78%) and non squamous-cell carcinoma (22%). HIV+ e HPV+ patients were 7 (6%) and 2 (2%), respectively. Median follow-up was 43 months (range: -132 months). The 5year LC rate was 83%. No significant association between 5year LC and clinicopathologic factors (age, T stage, N stage, histology, and HIV status) was recorded (p: NS). The 5-year DMFS was 93%. N stage was significantly correlated with 5year metastasis free survival (p<0.05). The 5-year OS was 73.5%. T status was significantly associated with 5 year OS (p= 0.035).
Conclusions:
Our results confirmed that radiochemotherapy
